Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06764875
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
840 Enrollment(s)
289 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-positive Gastric Cancer


Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
72 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-mutant Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT04739761
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
506 Enrollment(s)
81 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
150 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Unresectable Locally Recurrent Breast Cancer


Unresectable Locally Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT06271837
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
127 Enrollment(s)
29 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
NOT_YET_RECRUITING
NCT07547878
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
64 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Chronic Kidney Disease


Type 2 Diabetes
ACTIVE_NOT_RECRUITING
NCT06048718
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
28 Enrollment(s)
13 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


Metastatic Breast Cancer
RECRUITING
NCT05993234
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
257 Enrollment(s)
76 Study location(s)
OBSERVATIONAL (None)
HER2-positive Advanced Gastric Cancer


HER2-positive Gastroesophageal Junction Adenocarcinoma